FDA Circular No. 2020-022-A || EXTENSION OF THE EFFECTIVITY OF FDA CIRCULAR NO. 2020-022 ENTITLED “REISSUANCE OF THE GUIDELINES ON THE IDENTIFICATION, NOTIFICATION, EVALUATION, REGULATORY ENFORCEMENT ACTION, AND REVIEW AND MONITORING OF DONATED HEALTH PRODUCTS SOLELY INTENDED TO ADDRESS COVID-19 PUBLIC HEALTH EMERGENCY”

In the interest of service and due to the continuing COVID-19 Pandemic, the effectivity of FDA Circular No. 2020-022 entitled “Reissuance of the Guidelines on the Identification, Notification, Evaluation, Regulatory […]